Paul Karpecki, OD
Optometrist · Lexington, KYNPI 1619910569
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 16.9%. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,142 payments — averaging $1664.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$603K
- Oasis Medical, Inc.$321K
- Bausch & Lomb Americas Inc.$290K
- Biotissue Holdings Inc.$190K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$171K
- Harrow Eye, LLC$162K
- plus $1.8M from 52 others
Across 19 payments — averaging $4818.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$68K
- Glaukos Corporation$8K
- Novartis$8K
- Oyster Point Pharma, Inc.$3K
- Kala Pharmaceuticals, Inc.$3K
- Shire North American Group Inc$1K
- plus $739 from 1 others
What the payments were for
- Royalty or licence$32,8991%
- Consulting fees$1,902,85053%
- Speaking & faculty fees$1,368,80738%
- Travel & lodging$139,0704%
- Food & beverage$58,3812%
- Education$6,6740%
- Gifts$600%
- Entertainment$500%
- Other$55,6132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$623,663
- OASIS TEARS$278,644
- XIIDRA$210,242
- VEVYE$160,303
- CEQUA$138,134
- MIEBO$137,417
- Oxervate$106,817
- BIOTRUE$93,969
- Hydrus Microstent$81,113
- AdaptDx$76,173
- ULTRA$75,978
- RXSIGHT CONTACT LENS$69,654
- RXSIGHT INJECTOR CARTRIDGE$69,654
- RXSIGHT INJECTOR HANDPIECE$69,654
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$69,654
- AmnioGraft$64,941
- Hydrus$61,583
- Prokera$60,906
- AmnioGuard$60,772
- Keratograph$56,000
How this compares
$3,564,403 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 15 | $722,485 |
| XdemvyLotilaner | 150 | $281,981 |
| MieboPerfluorohexyloctane/Pf | 114 | $86,213 |
| XiidraLifitegrast | 49 | $47,273 |
| RestasisCyclosporine | 47 | $46,673 |
| VevyeCyclosporine | 24 | $19,803 |
| TyrvayaVarenicline Tartrate | 29 | $18,122 |
| LotemaxLoteprednol Etabonate | 16 | $5,521 |
| Cyclosporine | 19 | $4,068 |
| Prednisolone Acetate | 84 | $3,358 |
| FlarexFluorometholone Acetate | 17 | $2,463 |
| Fluorometholone | 26 | $1,866 |
| Doxycycline Hyclate | 12 | $882 |
| ValacyclovirValacyclovir Hcl | 14 | $343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $113,162 | $722,48515 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $128,629 | $281,981150 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $290,356 | $133,486163 claims |
| AbbVieRestasis | $62,722 | $46,67347 claims |
| Harrow Eye, LLCVevye | $161,576 | $19,80324 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $20,674 | $18,12229 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax | $171,442 | $5,52116 claims |
| Eyevance Pharmaceuticals LLCFlarex | $15,847 | $2,46317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Lexington
- Bilal AhmadLexington$150K
- Christopher KucLexington$52K
- Joe McMillinLexington$11K
- Karen McMillinLexington$10K
- Tania PatelLexington$6K
- Danielle FrankLexington$5K
- Ashley LaneLexington$5K
- Steven SpearLexington$5K
- Howell FindleyLexington$5K
- Lisa WangLexington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.